Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized safety study of four fixed-dose DU-176b regimens in nonvalvular atrial fibrillation
2007-001271-11Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of edoxaban in Atrial fibrillation (AFib), systemic embolism and stroke (5 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Incidence of elevated liver enzymes and/or bilirubin and Incidence of major and/or clinically relevant bleeding adverse events. Started Jul 2007; status: completed.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)systemic embolismstroke
Beyond the preview
Go deeper on 2007-001271-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001271-11.